GSK Shares Fall As Weaker Vaccine Sales Hit Earnings
Published 3h ago · Latest report 2h ago · Earnings
Affects United Kingdom
GSK shares dropped after falling vaccine sales in China hurt quarterly earnings.
Pharmaceutical giant GSK reported a 2% drop in quarterly vaccine sales to £2.6 billion. Weaker demand for its shingles and RSV shots, particularly in China, weighed on overall earnings and caused shares to slide.
- The figuresVaccine sales dropped 2% to £2.6 billion in the three months ending September 30.
- The causeReduced Chinese demand for shingles immunization drove the decline.
- The impactCompany shares fell following the lower-than-expected revenue report.
Written from 2 of 3 outlets — 1 has since joined this story.
1 new report since this summary was written 2h ago
Not in the AI summary yet. It is rewritten once enough new coverage arrives.
Why it matters
Pharmaceutical companies rely heavily on high-margin preventative vaccines for revenue growth. Shifts in regional demand, particularly in large markets like China, can significantly impact quarterly earnings and investor confidence.
By the numbers2
How outlets cover it
What outlets agree on
GSK experienced a drop in vaccine sales to £2.6 billion during the third quarter, driven by lower demand for shingles and RSV immunizations.
In this story
Covered by 3 outlets
67% of the sources are Left
Lean ratings via AllSides, Ad Fontes Media
- The GuardianAfter summaryGSK shares dive as weaker vaccine sales and restructuring charges unnerve investors2h ago · open ↗
- The IndependentGSK sees falling vaccine sales take shine off earnings2h ago · open ↗
- Financial TimesGSK shares slide after weaker vaccine sales3h ago · open ↗
Similar stories
What people are saying
Opens a search on that site in a new tab. Posts there are not ours and are not checked.
The headline, summary and key points are AI-generated from the sources above.
Comments